argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis | Business Wire
argenx | News
Press Releases | Argenx
SEC Filing | argenx
argenx on X: "Today we announced the continuation of our chronic inflammatory demyelinating polyneuropathy (CIDP) program following interim analysis of the Phase 2/3 ADHERE trial. Learn more here: https://t.co/0vgXZk0o0u https://t.co/iv5KRcJfH8" / X
ARGENX SE Form 6-K Current Report Filed 2023-01-09
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
Karen Gluck - Quality Control Editor - argenx | LinkedIn
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Argenx, Zai Lab Soar on Promising Data in CIDP - TipRanks.com
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy | Argenx
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Business Wire
argenx Announces U.S. Food and Drug Administration Approval
argenx | News
Genmab expands immunology reach in argenx pact
Argenx Follows up Phase III Success with Giant €785M Global Offering
Argenx gets FDA nod for first subcutaneous gMG therapy | pharmaphorum
Latest Healthcare and Pharma Press Release | Latest Healthcare News
Argenx: Next Phase Of Growth With Efgartigimod And ARGX-117 (NASDAQ:ARGX) | Seeking Alpha
argenx | News
